This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis and Antitumor Properties of Some Neutral Triesters of 5-Fluoro-2'-deoxyuridine-5'-monophosphate and 3',5'-Cyclic Monophosphate

J. -L. Girardet^a; G. Gosselin^a; C. Périgaud^a; J. Balzarini^b; E. De Clercq^b; J. -L. Imbach^a

^a Laboratoire de Chimie Bio-Organique, U.R.A. 488 du C.N.R.S., Universitéa Montpellier II, Montpellier Céadex, France ^b Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Girardet, J. -L. , Gosselin, G. , Périgaud, C. , Balzarini, J. , De Clercq, E. and Imbach, J. -L.(1995) 'Synthesis and Antitumor Properties of Some Neutral Triesters of 5-Fluoro-2'-deoxyuridine-5'-monophosphate and 3',5'-Cyclic Monophosphate', Nucleosides, Nucleotides and Nucleic Acids, 14: 3, 645 — 647

To link to this Article: DOI: 10.1080/15257779508012442 URL: http://dx.doi.org/10.1080/15257779508012442

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ANTITUMOR PROPERTIES OF SOME NEUTRAL TRIESTERS OF 5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE AND 3'.5'-CYCLIC MONOPHOSPHATE

J.-L. Girardet¹, G. Gosselin^{1*}, C. Périgaud¹, J. Balzarini², E. De Clercq² and J.-L. Imbach¹

¹Laboratoire de Chimie Bio-Organique, U.R.A. 488 du C.N.R.S., Université Montpellier II, Case Courrier 008, 34095 Montpellier Cédex 5, France; and ²Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.

Abstract: Several new prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate and 3',5'-cyclic monophosphate were synthesized and their antitumor activities were evaluated *in vitro*.

5-Fluoro-2'-deoxyuridine (FdUrd) is a clinically useful antitumor agent. It is converted intracellularly into 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUrdMP), which is a mechanism-based inhibitor of thymidylate synthetase. 1

With the aim to overcome the phosphorylation step of FdUrd, we synthesized several new neutral 5'-monophosphate and 3',5'-cyclic monophosphate derivatives of this compound (Fig. 1). In this regard, two kinds of bioreversible protective groups were used: the DTE 2 and the SATE 3 groups, which are liberated following a reductase- and an esterase-dependent activation process, respectively.

The in *vitro* antitumor activities of the newly synthesized compounds <u>1-4</u> were determined by measuring their inhibitory effects on the proliferation of several murine and human proliferating cells, including thymidine kinase deficient (TK⁻) cell lines (Table 1).

646 GIRARDET ET AL.

	RO PO OH	O P O NHO	
R=H	FdUrdMP	FdUrdcMP	
R=HO(CH ₂) ₂ SS(CH ₂) ₂ -	Bis(DTE)FdUrdMP (<u>1</u>)	(DTE)FdUrdcMP (<u>3</u>)	
R=CH ₃ COS(CH ₂) ₂ -	Bis(SATE)FdUrdMP (2)	(SATE)FdUrdcMP (4)	

FIGURE 1

TABLE 1

ĺ	CC ₅₀ (M)				
	FM3A/0	FM3A/TK-	CEM/0	CEM/TK-	Molt4F/Cl8
FUra	7.8 10-7	3.5 10-7	5.2 10-6	4.2 10-6	2.4 10-5
FdUrd	8.1 10-9	1.5 10-6	1.0 10-8	3.9 10-6	9.3 10-6
FdUrdMP	5.6 10-9	1.8 10-6	1.2 10-8	4.8 10-6	1.3 10-5
Bis(DTE)FdUrdMP	3.5 10-8	2.3 10-6	1.9 10-8	9.4 10-6	2.5 10-5
Bis(SATE)FdUrdMP	3.9 10-8	1.8 10-6	1.6 10-8	5.4 10-6	1.4 10-5
FdUrdcMP	2.3 10-7	1.4 10 ⁻⁵	2.9 10-7	6.8 10-5	9.8 10-5
(DTE)FdUrdcMP	4.6 10-8	7.9 10-6	2.0 10-7	3.6 10-5	3.0 10-5
(SATE)FdUrdcMP	5.7 10-8	4.4 10-6	2.6 10-7	2.0 10-5	6.6 10-6

 $50\,\%$ inhibitory effects (CC $_{50}$) on the proliferation of murine mammary carcinoma cells (FM3A, FM3A/TK-) and human T-lymphocyte cells (CEM/0, CEM/TK-, Molt4F/Cl8)

From the data presented in Table 1, it appears that:

- i) As expected, FdUrd is clearly much less active in TK⁻ cells than in TK⁺ cells. In all cells, FdUrdMP behaves as FdUrd, which means that this 5'-mononucleotide must be hydrolyzed extracellularly. Compared to FdUrd and FdUrdMP, FdUrdcMP shows a decreased inhibitory effect on all the cell lines.
- ii) The newly synthesized phosphotriesters **1** and **2**, as compared to the parent compounds FdUrd and FdUrdMP, do not show an increased activity against the TK⁻ cells. These results are not in accordance with the functioning of these phosphotriesters as intracellular delivery forms of the 5'-monophosphate (FdUrdMP).
- iii) The reduced activities of the cyclic phosphotriesters $\underline{3}$ and $\underline{4}$ suggest that either these compounds do not readily enter into the cells or they are not converted easily to FdUrdMP or FdUrd intracellularly.

Further work is currently in progress in our laboratory in order to explain why the nucleotide prodrug approach seems unsuccessful in the 5-fluorouracil series.

ACKNOWLEDGEMENTS

The presented investigations were supported by ARC "Agence pour la Recherche contre le Cancer" (FRANCE).

REFERENCES

- 1. Balzarini, J.; De Clercq, E.; Mertes, M. P.; Shugar, D.; Torrence, P. F. *Biochem. Pharmacol.* **1982**, <u>31</u>, 3673.
- 2. Puech, F.; Gosselin, G.; Lefebvre, I.; Pompon, A.; Aubertin, A.-M.; Kirn, A.; Imbach, J.-L. *Antiviral Res.* **1993**, 22, 155.
- 3. Périgaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J.-L.; Benzaria, S.; Barber, I.; Imbach, J.-L. *Bioorg. Med. Chem. Lett.* **1993**, <u>3</u>, 2521.